Evidence map›Paper›PMID 26496977›Full record

ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2015

Cardiovascular magnetic resonance findings in patients with PRKAG2 gene mutations.

Pauli Pöyhönen, Anita Hiippala, Laura Ollila, Touko Kaasalainen, Helena Hänninen, Tiina Heliö, Jonna Tallila, Catalina Vasilescu, Sari Kivistö, Tiina Ojala and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Mosaic pathogenicJHLT open · 2026
    Article
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Cardiac MR manifestations in two cases of PRKAG2 mutations in a Chinese family.The international journal of cardiovascular imaging · 2020
    Article
  18. Article
  19. Article
  20. Abnormal ECG Findings in Athletes: Clinical Evaluation and Considerations.Current treatment options in cardiovascular medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Pauli PöyhönenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Po BOX 340, Helsinki, 00029 HUCH, Finland. pauli.poyhonen@helsinki.fi.
Anita HiippalaChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. anita.hiippala@hus.fi.
Laura OllilaHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Po BOX 340, Helsinki, 00029 HUCH, Finland. laura.hupa@helsinki.fi.
Touko KaasalainenHUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. touko.kaasalainen@hus.fi.
Helena HänninenHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Po BOX 340, Helsinki, 00029 HUCH, Finland. helena.hanninen@hus.fi.
Tiina HeliöHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Po BOX 340, Helsinki, 00029 HUCH, Finland. tiina.helio@hus.fi.
Jonna TallilaBlueprint Genetics, Helsinki, Finland. jonna.tallila@blueprintgenetics.com.
Catalina VasilescuMolecular Neurology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. catalina.vasilescu@helsinki.fi.
Sari KivistöHUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. sari.kivisto@hus.fi.
Tiina OjalaChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. tiina.h.ojala@hus.fi.
Miia HolmströmHUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. miia.holmstrom@hus.fi.
Helsinki University Hospital · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutosomal dominantly inherited PRKAG2 cardiac syndrome is due to a unique defect of the cardiac cell metabolism and has a distinctive histopathology with excess intracellular glycogen, and prognosis different from sarcomeric hypertrophic cardiomyopathy. We aimed to define the distinct characteristics of PRKAG2 using cardiovascular magnetic resonance (CMR).

methodsCMR (1.5 T) and genetic testing were performed in two families harboring PRKAG2 mutations. On CMR, segmental analysis of left ventricular (LV) hypertrophy (LVH), function, native T1 mapping, and late gadolinium enhancement (LGE) were performed.

resultsSix individuals (median age 23 years, range 16-48; two females) had a PRKAG2 mutation: five with an R302Q mutation (family 1), and one with a novel H344P mutation (family 2). Three of six mutation carriers had LV mass above age and gender limits (203 g/m2, 157 g/m2 and 68 g/m2) and others (with R302Q mutation) normal LV masses. All mutation carriers had LVH in at least one segment, with the median maximal wall thickness of 13 mm (range 11-37 mm). Two R302Q mutation carriers with markedly increased LV mass (203 g/m2 and 157 g/m2) showed a diffuse pattern of hypertrophy but predominantly in the interventricular septum, while other mutation carriers exhibited a non-symmetric mid-infero-lateral pattern of hypertrophy. In family 1, the mutation negative male had a mean T1 value of 963 ms, three males with the R302Q mutation, LVH and no LGE a mean value of 918 ± 11 ms, and the oldest male with the R302Q mutation, extensive hypertrophy and LGE a mean value of 973 ms. Of six mutations carriers, two with advanced disease had LGE with 11 and 22 % enhancement of total LV volume.

conclusionsPRKAG2 cardiac syndrome may present with eccentric distribution of LVH, involving focal mid-infero-lateral pattern in the early disease stage, and more diffuse pattern but focusing on interventricular septum in advanced cases. In patients at earlier stages of disease, without LGE, T1 values may be reduced, while in the advanced disease stage T1 mapping may result in higher values caused by fibrosis. CMR is a valuable tool in detecting diffuse and focal myocardial abnormalities in PRKAG2 cardiomyopathy.

Indexed as

Magnetic Resonance Imaging, CineMutationAdolescentAdultAMP-Activated Protein KinasesCardiomyopathy, HypertrophicContrast MediaDNA Mutational AnalysisElectrocardiographyFemaleFibrosisGenetic Predisposition to DiseaseHumansHypertrophy, Left VentricularMaleMeglumineAMP-Activated Protein KinasesContrast Mediagadoterate meglumineMeglumineOrganometallic CompoundsPRKAG2 protein, human

Identifiers

PMID26496977
PMCPMC4619453
OpenAlexW2179562955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.